Related references
Note: Only part of the references are listed.A 5-Decade Analysis of Incidence Trends of Ischemic Stroke After Transient Ischemic Attack A Systematic Review and Meta-analysis
Shima Shahjouei et al.
JAMA NEUROLOGY (2021)
Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial
Yongjun Wang et al.
STROKE AND VASCULAR NEUROLOGY (2021)
Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial
Xia Meng et al.
STROKE AND VASCULAR NEUROLOGY (2021)
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial
Naveen L. Pereira et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial
Yilong Wang et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Daniel M. F. Claassens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials
Yuesong Pan et al.
JAMA NEUROLOGY (2019)
Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes The PHARMCLO Trial
Francesca Maria Notarangelo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial
Philip M. Bath et al.
LANCET (2018)
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
S. Claiborne Johnston et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack A Systematic Review and Meta-Analysis
Yuesong Pan et al.
CIRCULATION (2017)
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack
Yilong Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack
S. Claiborne Johnston et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke
Pierre Amarenco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
Yongjun Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inhibition of platelet aggregation by AZD6140, A reversible oral P2Y12 receptor antagonist, compared with clopidogral in patients with acute coronary syndrome
Robert F. Storey et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Share Paper
